Insights

Our experience drives our insights, boostering trustworthy relationships with our clients.

Publications & MoreAll Publications

Publication

From innovation to sanctions?

Routine practice data collection

Publication

The Pathology of Niemann-Pick Type C

in Pediatric and Adult Patients

Publication

Gene therapies

Gaps between theoretical assessment, practical benefit and reimbursement

Publication

Outcomes of Benefit Assessments

of Orphan Drugs Without Orphan Designation in Germany

Blog articlesAll Blog articles

Blog

General methods for IQWiG's benefit assessment

Version 7.0 of the methods paper is now valid

Blog

EUnetHTA 21 service contract ends.

The countdown to 2025 is on.

Blog

The designation practice of the G-BA of combination partners is strongly criticized.

Combination therapies

Blog

SKC podcast

#14 Update from Brussels – between EU-HTA and Pharma Package

EventsAll Events

Event

Web Summit 2023

13th to 16th of Nov 2023

Marius Luding

Meet us at the world's largest tech conference.

Event

ISPOR Europe

12th to 15th of Nov 2023

Prof. Matthias P. Schönermark, M.D., Ph.D.

Visit us at our booth C2-043.

Event

World Orphan Drug Congress 2023

30th of Oct to 2nd of Nov 2023

Dipl.-Kauffrau Heike Kielhorn-Schönermark

Strategy, advocacy and partnering for the orphan drug industry

Event

Access Europe 23

2nd to 4th of Oct 2023

Prof. Matthias P. Schönermark, M.D., Ph.D.

Excellence for Market & Patient Access, Pricing and Reimbursement

Orphan DrugsAll about Orphan Drugs

Orphan Drugs

Orphan drugs in Germany

Orphan Drugs

Whitepaper: Orphan drugs in Germany

Lessons learned from 10 years AMNOG, best and worst practices

Orphan Drugs

The Profcast - rare diseases and their therapies

Orphan Drugs

AMNOG orphan tracker

to the top